Jolanta Krajewska

Summary

Affiliation: Gliwice Branch
Country: Poland

Publications

  1. ncbi request reprint Treatment with sorafenib in advanced thyroid cancer - a case report
    Jolanta Krajewska
    Nuclear Medicine and Endocrine Oncology Department, Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology, Gliwice Branch, Poland
    Endokrynol Pol 61:492-6. 2010
  2. doi request reprint Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients
    Jolanta Krajewska
    Nuclear Medine and Endocrine Oncology Department M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch
    Endokrynol Pol 67:2-11. 2016
  3. pmc Prognostic value of lymph node metastases of differentiated thyroid cancer (DTC) according to the local advancement and range of surgical excision
    Agnieszka Czarniecka
    M, Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland
    Thyroid Res 3:8. 2010
  4. ncbi request reprint Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer
    Daria Handkiewicz-Junak
    Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland
    J Nucl Med 48:879-88. 2007
  5. ncbi request reprint [Relapse of differentiated thyroid carcinoma in low-risk patients]
    Jolanta Krajewska
    Department of Nuclear Medicine and Endocrine Oncology, Comprehensive Cancer Center and M Sklodowska Curie Memorial Institute of Oncology, Gliwice Branch, Gliwice
    Endokrynol Pol 57:386-91. 2006
  6. ncbi request reprint [Evaluation of the therapeutic benefits in relation to the extent of surgery in patients with differentiated thyroid carcinoma]
    Agnieszka Czarniecka
    Centre of Oncology, Maria Sklodowska Curie Memorial Institute, Gliwice Branch, Gliwice
    Endokrynol Pol 57:362-9. 2006
  7. ncbi request reprint [Completion total thyroidectomy in children with differentiated thyroid cancer]
    Daria Handkiewicz-Junak
    Nuclear Medicine and Endocrine Oncology Department, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice
    Endokrynol Pol 57:356-61. 2006
  8. ncbi request reprint [Indications for surgery of thyroid cancer based on bioptate molecular examination]
    Elżbieta Gubała
    Department of Nuclear Medicine and Endocrine Oncology, Comprehensive Cancer Center and M Sklodowska Curie Memorial Institute of Oncology, Gliwice Branch, Gliwice
    Endokrynol Pol 57:396-402. 2006
  9. pmc Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi
    Aleksandra Kukulska
    Department of Nuclear Medicine and Endocrine Oncology, M, Skłodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland
    Thyroid Res 3:9. 2010
  10. ncbi request reprint Has differentiated thyroid cancer (DTC) staging changed with in the last ten years in the Silesia region of Poland?
    Barbara Michalik
    Department of Nuclear Medicine and Endocrine Oncolgy, Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology, Gliwice Branch, Poland
    Endokrynol Pol 61:480-4. 2010

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Treatment with sorafenib in advanced thyroid cancer - a case report
    Jolanta Krajewska
    Nuclear Medicine and Endocrine Oncology Department, Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology, Gliwice Branch, Poland
    Endokrynol Pol 61:492-6. 2010
    ..We present this case to document no adverse effects of therapy with sorafenib in a patient with brain DTC metastases. Sorafenib therapy was only short-term, but no progression occurred in this time...
  2. doi request reprint Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients
    Jolanta Krajewska
    Nuclear Medine and Endocrine Oncology Department M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch
    Endokrynol Pol 67:2-11. 2016
    ..Adequate postoperative risk assessment currently constitutes the principle of DTC treatment and further management. The aim of the study - a retrospective assessment of risk factors influencing DTC relapse...
  3. pmc Prognostic value of lymph node metastases of differentiated thyroid cancer (DTC) according to the local advancement and range of surgical excision
    Agnieszka Czarniecka
    M, Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland
    Thyroid Res 3:8. 2010
    ..The analysis of prognostic significance of LN metastases, in DTC patients to verify the potential role of central neck lymphadenectomy on disease staging...
  4. ncbi request reprint Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer
    Daria Handkiewicz-Junak
    Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland
    J Nucl Med 48:879-88. 2007
    ....
  5. ncbi request reprint [Relapse of differentiated thyroid carcinoma in low-risk patients]
    Jolanta Krajewska
    Department of Nuclear Medicine and Endocrine Oncology, Comprehensive Cancer Center and M Sklodowska Curie Memorial Institute of Oncology, Gliwice Branch, Gliwice
    Endokrynol Pol 57:386-91. 2006
    ..The aim of the study was to analyze the impact of the routine follow up examinations for early detection of DTC recurrence in low risk DTC patients...
  6. ncbi request reprint [Evaluation of the therapeutic benefits in relation to the extent of surgery in patients with differentiated thyroid carcinoma]
    Agnieszka Czarniecka
    Centre of Oncology, Maria Sklodowska Curie Memorial Institute, Gliwice Branch, Gliwice
    Endokrynol Pol 57:362-9. 2006
    ..Evaluation of the therapeutic benefits in relation to the stage of thyroid cancer and to the extent of surgery and the risk of postoperative complications...
  7. ncbi request reprint [Completion total thyroidectomy in children with differentiated thyroid cancer]
    Daria Handkiewicz-Junak
    Nuclear Medicine and Endocrine Oncology Department, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice
    Endokrynol Pol 57:356-61. 2006
    ..Especially the need for completion operation is questioned in young patients. Our objective was to examine the rate of residual neoplastic disease after non radical initial operation...
  8. ncbi request reprint [Indications for surgery of thyroid cancer based on bioptate molecular examination]
    Elżbieta Gubała
    Department of Nuclear Medicine and Endocrine Oncology, Comprehensive Cancer Center and M Sklodowska Curie Memorial Institute of Oncology, Gliwice Branch, Gliwice
    Endokrynol Pol 57:396-402. 2006
    ..The aim of the study was to assess the results of fine needle aspiration (FNA) samples examination by the use of RT-PCR for Tg mRNA. The special attention was directed to the evaluation of specificity of TgRNA estimation...
  9. pmc Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi
    Aleksandra Kukulska
    Department of Nuclear Medicine and Endocrine Oncology, M, Skłodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland
    Thyroid Res 3:9. 2010
    ....
  10. ncbi request reprint Has differentiated thyroid cancer (DTC) staging changed with in the last ten years in the Silesia region of Poland?
    Barbara Michalik
    Department of Nuclear Medicine and Endocrine Oncolgy, Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology, Gliwice Branch, Poland
    Endokrynol Pol 61:480-4. 2010
    ..The aim of the study was to compare the advancement of thyroid cancer at diagnosis in Polish patients from the Silesian district in the years 1999 and 2008...
  11. pmc The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors
    Agnieszka Czarniecka
    The Oncologic and Reconstructive Surgery Clinic, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland
    PLoS ONE 10:e0132821. 2015
    ..The question arises whether this factor is useful in smaller populations, characterised for specialised centres. Thus, the aim of the study was to evaluate the use of BRAF mutation as a potential predictive marker in PTC patients...
  12. ncbi request reprint Occurrence of BRAF mutations in a Polish cohort of PTC patients - preliminary results
    Agnieszka Czarniecka
    Department of Oncological and Reconstructive Surgery, MSC Memorial Cancer Centre and Institute of Oncology, Gliwice Branch, Poland
    Endokrynol Pol 61:462-6. 2010
    ..BRAF (V600E) mutation was diagnosed in 38 (43%) of cases...
  13. ncbi request reprint [Clinical course and treatment of patients with differentiated thyroid carcinoma diagnosed during the year 1995]
    Agnieszka Czarniecka
    Center of Oncology M Sklodowska Curie Memorial Institute, Gliwice, Poland
    Endokrynol Pol 56:758-65. 2005
    ..Cancer, 2000) was also performed in this study. We conclude that DTC therapy, currently recommended in our country, gives satisfactory results and that clinical outcome and therapeutic methods are similar both in Poland and Germany...
  14. ncbi request reprint Germinal mutations of RET, SDHB, SDHD, and VHL genes in patients with apparently sporadic pheochromocytomas and paragangliomas
    Aleksandra Krawczyk
    Department of Nuclear Medicine and Endocrine Oncology, Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology, Gliwice Branch, Poland
    Endokrynol Pol 61:43-8. 2010
    ..Clinical presentation can sometimes be atypical and does not always allow proper diagnosis. In such situations, DNA analysis can be helpful, especially when the pheochromocytoma is the first and only symptom...
  15. doi request reprint Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer
    Daria Handkiewicz-Junak
    Department of Nuclear Medicine and Endocrine OncologyMaria Sklodowska Curie Memorial Institute and Centre of Oncology, Gliwice Branch, Wybrzeze Armii Krajowej 14, 44 100 Gliwice, Poland
    Eur J Endocrinol 173:873-81. 2015
    ..The aim of our retrospective study was to evaluate outcomes of adjuvant, rhTSH-aided radioiodine treatment in children/adolescents with DTC and to compare them to (131)I therapy during l-thyroxin withdrawal (THW)...
  16. pmc Timing and criteria for prophylactic thyroidectomy in asymptomatic RET carriers - the role of Ct serum level
    Barbara Jarzab
    Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44 101 Gliwice, Poland
    Thyroid Res 6:S9. 2013
    ....
  17. ncbi request reprint Urinary iodine in patients with differentiated thyroid cancer (DTC) during L-thyroxine treatment
    Barbara Michalik
    Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology, Gliwince Branch, Gliwice, Poland
    Endokrynol Pol 61:458-61. 2010
    ..Urinary iodine concentrations were analyzed in the morning urine samples of patients with differentiated thyroid cancer (DTC)...
  18. ncbi request reprint [The impact of the extent and time of operation on the survival in patients with differentiated thyroid carcinoma (DTC)]
    Agnieszka Czarniecka
    Centre of Oncology, Maria Sklodowska Curie Memorial Institute, Branch Gliwice, Gliwice
    Endokrynol Pol 57:347-55. 2006
    ..To analyze the impact of time and extent of operation on overall and disease-free survival in patients with differentiated thyroid carcinoma (DTC)...
  19. pmc Differences in Gene-Gene Interactions in Graves' Disease Patients Stratified by Age of Onset
    Beata Jurecka-Lubieniecka
    Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland
    PLoS ONE 11:e0150307. 2016
    ..In the present study, we analyzed the effects of the interactions of multiple loci on the genetic predisposition to GD. The aim of our analyses was to identify pairs of genes that exhibit a multiplicative interaction effect...
  20. pmc BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma
    Dagmara Rusinek
    Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland
    PLoS ONE 10:e0143688. 2015
    ..The most frequent genetic alteration in PTC is the BRAFV600E mutation--its impact may extend even beyond PTC genomic profile and influence the tumor characteristics and even clinical behavior...
  21. doi request reprint Drug safety evaluation of lenvatinib for thyroid cancer
    Jolanta Krajewska
    a Nuclear Medicine and Endocrine Oncology Department, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland
    Expert Opin Drug Saf 14:1935-43. 2015
    ..Although a lot of them were manageable, in 35-68% of patients dose reduction was required. Nevertheless, only 15% of subjects withdrew the drug due to its toxicity...
  22. doi request reprint Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer
    Jolanta Krajewska
    a Nuclear Medicine and Endocrine Oncology Department, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland
    Expert Rev Clin Pharmacol 9:69-79. 2016
    ..Expert Commentary: Cabozantinib constitutes an effective treatment option with acceptable toxicity in MTC patients showing either germinal or sporadic tumor RET M918T mutation as the drug prolonged OS in these subjects. ..
  23. doi request reprint Sorafenib for the treatment of thyroid cancer: an updated review
    Jolanta Krajewska
    Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Nuclear Medicine and Endocrine Oncology Department, Gliwice Branch, Gliwice, Poland 48 32 2789301 48 32 2789310
    Expert Opin Pharmacother 16:573-83. 2015
    ....
  24. doi request reprint Novel therapies for thyroid cancer
    Jolanta Krajewska
    M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Nuclear Medicine and Endocrine Oncology Department, Gliwice, Poland
    Expert Opin Pharmacother 15:2641-52. 2014
    ..Their efficacy was demonstrated in Phase III studies, compared to placebo; each of them significantly prolonged the progression-free survival...